









Markets
/
Stocks
/
nasdaq-atxs
/

Astria Therapeutics Inc

ATXS

View Detailed Chart

6.560USD

0.0000.00%

Close 08/01, 16:00（ET）Quotes delayed by 15 min

370.21MMarket Cap

LossP/E TTM



Astria Therapeutics Inc

6.560

0.0000.00%

Overview Company Financials

Financials

Intraday

30m

Today

-5.20%

5 Days

-1.35%

1 Month

+12.91%

6 Months

-11.71%

Year to Date

-26.62%

1 Year

-37.22%

View Detailed Chart

Agency Rating

Analyst Rating

Based on 9 analysts

BUY

Current Rating

29.125

Target Price

343.98%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

552

Total

Median

Average

Company name

Ratings

Analysts

Astria Therapeutics Inc

ATXS

CRISPR Therapeutics AG

CRSP

Intellia Therapeutics Inc

NTLA

Ionis Pharmaceuticals Inc

IONS

Exact Sciences Corp

EXAS

IQVIA Holdings Inc

IQV

...

111

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

15m

30m

15m

30m

D

Sell

Sell(7)

Neutral(3)

Buy(3)

Indicators

Sell(4)

Neutral(3)

Buy(0)

Indicators

Value

Direction

MACD(12,26,9)

-0.020

Neutral

RSI(14)

55.854

Neutral

STOCH(KDJ)(9,3,3)

50.190

Sell

ATR(14)

0.365

Low Volatility

CCI(14)

50.790

Neutral

Williams %R

55.730

Sell

TRIX(12,20)

0.629

Sell

StochRSI(14)

0.000

Sell

Moving Average

Sell(3)

Neutral(0)

Buy(3)

Indicators

Value

Direction

MA5

6.698

Sell

MA10

6.606

Sell

MA20

6.498

Buy

MA50

5.772

Buy

MA100

5.420

Buy

MA200

7.224

Sell

News

More news coming soon, stay tuned...

Financial Indicators

EPS

No Data

Total revenue

No Data

Company

Astria Therapeutics, Inc. is a biopharmaceutical company focused on developing therapies for allergic and immunological diseases. The Company's lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development for the treatment of hereditary angioedema (HAE), a rare, debilitating and potentially life-threatening disease. Its second program, STAR-0310, is a monoclonal antibody OX40 antagonist in preclinical development for the treatment of atopic dermatitis (AD). The Company owns two patent families directed to STAR-0215. The first patent family is directed to the composition of matter of its product candidate STAR-0215 and its use in treating various plasma kallikrein associated disorders including HAE. In the second patent family, the Company owns one International (PCT) patent application directed to methods of treating various plasma-kallikrein associated disorders, including HAE, with specific dosing regimens of the STAR-0215 antibody.

Ticker SymbolATXS

CompanyAstria Therapeutics Inc

CEODr. Jill C. Milne, Ph.D.

Websitehttps://astriatx.com/